Biology of Blood and Marrow Transplantation
Volume 13, Issue 11 , Pages 1369-1379 , November 2007

Central Nervous System Complications after Allogeneic Hematopoietic Stem Cell Transplantation: Incidence, Manifestations, and Clinical Significance

  • Deborah Siegal

      Affiliations

    • Blood and Marrow Transplant Program, University Health Network, Toronto, Canada
    • ,
  • Anne Keller

      Affiliations

    • Department of Radiology, University Health Network, Toronto, Canada
    • ,
  • Wei Xu

      Affiliations

    • Department of Biostatistics, Princess Margaret Hospital, University of Toronto, Toronto, Canada
    • ,
  • Sandeep Bhuta

      Affiliations

    • Department of Radiology, University Health Network, Toronto, Canada
    • ,
  • Dong Hwan Kim

      Affiliations

    • Blood and Marrow Transplant Program, University Health Network, Toronto, Canada
    • ,
  • John Kuruvilla

      Affiliations

    • Blood and Marrow Transplant Program, University Health Network, Toronto, Canada
    • ,
  • Jeffrey H. Lipton

      Affiliations

    • Blood and Marrow Transplant Program, University Health Network, Toronto, Canada
    • ,
  • Hans Messner

      Affiliations

    • Blood and Marrow Transplant Program, University Health Network, Toronto, Canada
    • ,
  • Vikas Gupta

      Affiliations

    • Blood and Marrow Transplant Program, University Health Network, Toronto, Canada
    • Corresponding Author InformationCorrespondence and reprint requests: Vikas Gupta, MD, MRCP, MRCPath, Blood and Marrow Transplant Program, Princess Margaret Hospital, Suite 5-217, 610 University Avenue, Toronto, M5G 2 M9, ON, Canada.

Received 22 June 2007 ,Accepted 24 July 2007.

References 

  1. Antonini G, Ceschin V, Morino S, et al. Early neurologic complications following allogeneic bone marrow transplant for leukemia: a prospective study. Neurology. 1998;50:1441–1445
  2. de Brabander C, Cornelissen J, Smitt PA, Vecht CJ, van den Bent MJ. Increased incidence of neurological complications in patients receiving an allogenic bone marrow transplantation from alternative donors. J Neurol Neurosurg Psychiatry. 2000;68:36–40
  3. Faraci M, Lanino E, Dini G, et al. Severe neurologic complications after hematopoietic stem cell transplantation in children. Neurology. 2002;59:1895–1904
  4. Gallardo D, Ferra C, Berlanga JJ, et al. Neurologic complications after allogeneic bone marrow transplantation. Bone Marrow Transplant. 1996;18:1135–1139
  5. Graus F, Saiz A, Sierra J, et al. Neurologic complications of autologous and allogeneic bone marrow transplantation in patients with leukemia: a comparative study. Neurology. 1996;46:1004–1009
  6. Guerrero A, Perez-Simon JA, Gutierrez N, et al. Neurological complications after autologous stem cell transplantation. Eur Neurol. 1999;41:48–50
  7. Iguchi A, Kobayashi R, Yoshida M, et al. Neurological complications after stem cell transplantation in childhood. Bone Marrow Transplant. 1999;24:647–652
  8. Kishi Y, Miyakoshi S, Kami M, et al. Early central nervous system complications after reduced-intensity stem cell transplantation. Biol Blood Marrow Transplant. 2004;10:561–568
  9. Reece DE, Frei-Lahr DA, Shepherd JD, et al. Neurologic complications in allogeneic bone marrow transplant patients receiving cyclosporin. Bone Marrow Transplant. 1991;8:393–401
  10. Sostak P, Padovan CS, Yousry TA, Ledderose G, Kolb HJ, Straube A. Prospective evaluation of neurological complications after allogeneic bone marrow transplantation. Neurology. 2003;60:842–848
  11. Uckan D, Cetin M, Yigitkanli I, et al. Life-threatening neurological complications after bone marrow transplantation in children. Bone Marrow Transplant. 2005;35:71–76
  12. Mohrmann RL, Mah V, Vinters HV. Neuropathologic findings after bone marrow transplantation: an autopsy study. Hum Pathol. 1990;21:630–639
  13. Bleggi-Torres LF, de Medeiros BC, Werner B, et al. Neuropathological findings after bone marrow transplantation: an autopsy study of 180 cases. Bone Marrow Transplant. 2000;25:301–307
  14. Bartynski WS, Zeigler ZR, Shadduck RK, Lister J. Variable incidence of cyclosporine and FK-506 neurotoxicity in hematopoeitic malignancies and marrow conditions after allogeneic bone marrow transplantation. Neurocrit Care. 2005;3:33–45
  15. Chohan R, Vij R, Adkins D, et al. Long-term outcomes of allogeneic stem cell transplant recipients after calcineurin inhibitor-induced neurotoxicity. Br J Haematol. 2003;123:110–113
  16. Bartynski WS, Zeigler Z, Spearman MP, Lin L, Shadduck RK, Lister J. Etiology of cortical and white matter lesions in cyclosporin-A and FK-506 neurotoxicity. AJNR Am J Neuroradiol. 2001;22:1901–1914
  17. Trullemans F, Grignard F, Van Camp B, Schots R. Clinical findings and magnetic resonance imaging in severe cyclosporine-related neurotoxicity after allogeneic bone marrow transplantation. Eur J Haematol. 2001;67:94–99
  18. Bartynski WS, Zeigler ZR, Shadduck RK, Lister J. Pretransplantation conditioning influence on the occurrence of cyclosporine or FK-506 neurotoxicity in allogeneic bone marrow transplantation. AJNR Am J Neuroradiol. 2004;25:261–269
  19. Zimmer WE, Hourihane JM, Wang HZ, Schriber JR. The effect of human leukocyte antigen disparity on cyclosporine neurotoxicity after allogeneic bone marrow transplantation. AJNR Am J Neuroradiol. 1998;19:601–660[discussion 9-10]
  20. Cohen RB, Abdallah JM, Gray JR, Foss F. Reversible neurologic toxicity in patients treated with standard-dose fludarabine phosphate for mycosis fungoides and chronic lymphocytic leukemia. Ann Intern Med. 1993;118:114–116
  21. Spriggs DR, Stopa E, Mayer RJ, Schoene W, Kufe DW. Fludarabine phosphate (NSC 312878) infusions for the treatment of acute leukemia: phase I and neuropathological study. Cancer Res. 1986;46:5953–5958
  22. Vidarsson B, Mosher DF, Salamat MS, Isaksson HJ, Onundarson PT. Progressive multifocal leukoencephalopathy after fludarabine therapy for low-grade lymphoproliferative disease. Am J Hematol. 2002;70:51–54
  23. Warrell RP, Berman E. Phase I and II study of fludarabine phosphate in leukemia: therapeutic efficacy with delayed central nervous system toxicity. J Clin Oncol. 1986;4:74–79
  24. Mayer RJ, Davis RB, Schiffer CA, et al. Intensive postremission chemotherapy in adults with acute myeloid leukemia (Cancer and Leukemia Group B). N Engl J Med. 1994;331:896–903
  25. Fyles GM, Messner HA, Lockwood G, et al. Long-term results of bone marrow transplantation for patients with AML, ALL and CML prepared with single dose total body irradiation of 500 cGy delivered with a high dose rate. Bone Marrow Transplant. 1991;8:453–463
  26. Gupta V, Yi QL, Brandwein J, et al. The role of allogeneic bone marrow transplantation in adult patients below the age of 55 years with acute lymphoblastic leukemia in first complete remission: a donor vs no donor comparison. Bone Marrow Transplant. 2004;33:397–404
  27. Kiss TL, Panzarella T, Messner HA, et al. Busulfan and cyclophosphamide as a preparative regimen for allogeneic blood and marrow transplantation in patients with non-Hodgkin’s lymphoma. Bone Marrow Transplant. 2003;31:73–78
  28. Gupta V, Chun K, Yi QL, et al. Disease biology rather than age is the most important determinant of survival of patients > or = 60 years with acute myeloid leukemia treated with uniform intensive therapy. Cancer. 2005;103:2082–2090
  29. Gupta V, Daly A, Lipton JH, et al. Nonmyeloablative stem cell transplantation for myelodysplastic syndrome or acute myeloid leukemia in patients 60 years or older. Biol Blood Marrow Transplant. 2005;11:764–772
  30. Casey SO, Sampaio RC, Michel E, Truwit CL. Posterior reversible encephalopathy syndrome: utility of fluid-attenuated inversion recovery MR imaging in the detection of cortical and subcortical lesions. AJNR Am J Neuroradiol. 2000;21:1199–1206
  31. Hinchey J, Chaves C, Appignani B, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334:494–500
  32. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706
  33. Kaplan E, Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc. 1958;53:457–481
  34. Wong R, Beguelin GZ, de Lima M, et al. Tacrolimus-associated posterior reversible encephalopathy syndrome after allogeneic haematopoietic stem cell transplantation. Br J Haematol. 2003;122:128–134
  35. Erer B, Polchi P, Lucarelli G, et al. CsA-associated neurotoxicity and ineffective prophylaxis with clonazepam in patients transplanted for thalassemia major: analysis of risk factors. Bone Marrow Transplant. 1996;18:157–162
  36. Lucey MR, Kolars JC, Merion RM, Campbell DA, Aldrich M, Watkins PB. Cyclosporin toxicity at therapeutic blood levels and cytochrome P-450 IIIA. Lancet. 1990;335:11–15
  37. Thompson CB, June CH, Sullivan KM, Thomas ED. Association between cyclosporin neurotoxicity and hypomagnesaemia. Lancet. 1984;2:1116–1120

PII: S1083-8791(07)00370-9

doi: 10.1016/j.bbmt.2007.07.013

Biology of Blood and Marrow Transplantation
Volume 13, Issue 11 , Pages 1369-1379 , November 2007

Article Tools

* Image Usage & Resolution